Much of the information that medicine needs to know about a patient's health status is still obtained through blood draws and other tests that involve punctures. For many patients, needles and extractions are part of their routine: from people admitted to the hospital, who may need frequent checks, to those living with a chronic illness, such as diabetes, who must regularly monitor their glucose levels. In recent years, however, new technologies have emerged that allow some aspects of the body to be monitored without the need for punctures. Smartwatches are an example: they allow measuring heart rate, recording physical activity, or controlling body temperature.
But the body can offer much more information than these devices collect. Sweat, which is usually associated with physical exertion or heat, also contains substances that can help to better understand what is happening inside the body. Harnessing this information hidden in sweat is precisely the challenge of the Barcelona-based startup Onalabs, which has been developing technology for almost a decade to analyze it and explore what information it can provide about health, both in sports and medical fields. "Sweat can help us know what is happening inside the body without having to do a blood draw or any other invasive test," defends Elisabet del Valle, co-founder and CEO of the company.
Such technology could be especially useful in the hospital setting and in the monitoring of chronic diseases, as it would allow obtaining information about a person's health status without constantly resorting to punctures. In the case of admitted patients, for example, it could avoid some of the blood draws that are done during the night and often interrupt rest. A similar need arises in people with diabetes, who must regularly monitor their glucose levels. Although they currently have continuous sensors that reduce the need to prick their fingers several times a day, many of these devices still require inserting a small filament under the skin and wearing it permanently.
This need is even more evident in the case of babies, as they have a much lower blood volume than an adult and extractions can represent a significant loss in proportion to their size. In fact, avoiding these punctures in babies was what led Xavier Muñoz and Elisabet del Valle to promote Onalabs just a decade ago, at the end of 2016, following a personal experience. One of Muñoz's daughters was born with a congenital heart defect and spent several months hospitalized. During that period, blood extractions were frequent, a situation that made Muñoz and del Valle wonder if there was another way to monitor a patient's health without having to continuously extract blood.
They found the answer in sweat and soon discovered that the potential of information about the human body that can be obtained through this fluid went far beyond the initial idea. Although the first project was designed for babies hospitalized, it was a small market and it was difficult to attract private investment, according to del Valle. For this reason, they decided to reorient the strategy towards sports, an area with more growth possibilities and where they could develop and validate the technology with fewer regulatory demands than in the medical sector.
Sweat at the service of sports performance
After almost a decade dedicated to developing its technology and demonstrating its potential —a work that has also resulted in six patents—, Onalabs is beginning to enter the market and is now facing a new stage of growth. To boost it, the company has closed a financing round of more than 9.3 million euros this year, led by the Spanish Society for Technological Transformation (SETT), which contributes 4.6 million through the Next Tech instrument. The operation also involves funds such as 1921 Ventures, specialized in diabetes, and nPrime, based in Singapore, as well as strategic partners Reig Patrimonia and WA4STEAM.
This funding is in addition to other previous operations, such as the 1.5 million euro seed round in 2022 and another 1.8 million in 2023, in which FC Barcelona also joined as a strategic partner of the startup. In addition, the company has received more than four million euros in public aid. All this funding has allowed them to develop their first two devices: ONASPORT, focused on monitoring sports performance through sweat analysis, and ONAVITAL, a wristband that allows continuous monitoring of different vital signs, such as blood pressure, heart rate, or blood oxygen saturation.
In the case of ONASPORT, the device has the format of a chest heart rate monitor, but incorporates a disposable patch that adheres to the skin and a microchannel that collects sweat for analysis. Every minute, the system extracts data that allows controlling the amount of sweat, the degree of dehydration, and the loss of electrolytes, such as sodium, as well as estimating lactate levels, a substance produced by muscles during physical activity —which is usually measured through blood, from a finger or ear prick— and which helps assess the body's response to effort. All this information is transmitted to a mobile application, from where athletes can consult and analyze their training sessions, and can also be integrated into smart devices such as Garmin watches. In this way, they can monitor how their body responds to effort and adjust both training intensity and hydration.
Although the device has already entered the market and has been tested in reference centers such as CAR Sant Cugat, INEFC, and Clínica Ergodinàmica, for now, few units are manufactured. So far, ONASPORT has reached individual athletes and has collaborated with teams such as Girona, while FC Barcelona is a strategic partner of the company. But the most important leap is yet to come: Onalabs plans to start commercializing the device on a large scale during 2027, with Europe as the first market, although it is also studying expanding to countries in the Middle East, Asia, and the United States. Del Valle trusts that that year the company will be able to "achieve a first more significant turnover volume," which would represent a turning point after almost a decade dedicated to research and technology development.
The leap from sport to hospitals
But, in addition to sports performance, Onalabs keeps its focus on the medical applications of its technology with ONAVITAL, a wristband that, unlike ONASPORT, does not analyze sweat, but incorporates its own optical sensors to continuously measure vital signs such as blood pressure, heart rate, oxygen saturation, and skin temperature. The device has already been tested at the Germans Trias i Pujol Hospital and the company is working with several healthcare centers on pilot projects to study how to integrate it into patient monitoring, both in the hospital and at home. In a hospital, for example, it would allow monitoring the vital signs of admitted patients "without having to wake them up during the night to take measurements," explains the co-founder.
However, to reach hospitals, ONAVITAL still needs to obtain European certification as a medical device. Del Valle is confident that authorization will arrive this year and allow commercialization in hospitals to begin as soon as possible. In addition, outside hospitals, the wristband could also have applications in residences and in monitoring elderly people living alone.
Beyond these two devices —ONASPORT, which has already reached the market, and ONAVITAL, which is preparing to do so—, Onalabs continues to explore how far sweat analysis can go. One of the company's main lines of research focuses on diabetes, with the aim of creating a device that allows monitoring glucose levels without having to resort to punctures. The company, however, has also not abandoned the purpose that drove its creation: to find a way to monitor the health of hospitalized babies without having to take blood samples. Thus, almost a decade later, that first objective is still part of Onalabs' horizons.